...has completed Phase Ia testing to treat solid tumors. Forbius itself was spun out of YM Biosciences Inc....

...idelalisib (CAL-101) Ph II Cancer 2011 $375M + up to $225M ms Mkt; $92M (1%) YM BioSciences Inc....

...provide details. Gilead gained rights to momelotinib in 2012 through its $510 million acquisition of YM Biosciences Inc....

...and JAK-2 inhibitor from Incyte Corp. (NASDAQ:INCY). Gilead gained momelotinib via its 2012 acquisition of YM BioSciences Inc....

...and gemcitabine for previously untreated metastatic pancreatic cancer. Gilead acquired the compound when it bought YM BioSciences...

...of cancer company Ceptaris Therapeutics Inc. , antibiotics play Rempex Pharmaceuticals Inc. and cancer company YM BioSciences Inc....
...up front plus up to $334 million in milestones. Gilead Sciences Inc. (NASDAQ:GILD) took out YM BioSciences...

...Mich. Business: Cancer Hired: Nick Glover as president and CEO, formerly president and CEO of YM BioSciences Inc....

...glioma. InnoMab Pte. Ltd., a JV between CIMAB and InnoKeys, purchased nimotuzumab in 2012 from YM BioSciences Inc....

...exclusive license from Cytopia Ltd. to develop PDGFR inhibitors for PAH under a 2007 deal. YM BioSciences Inc....

...SVP and CMO, a newly created position, formerly VP of regulatory affairs and CMO of YM BioSciences Inc....